$STT State Street Tape Reports
Per Ticker.id: $STT State Street Tape Reports — 8 podcast mentions across 4 podcasts (30 days), latest 2026-08-26 16:00 UTC.
usually the release valve for this is weaker currency. Problem is that every currency— remember, currency exchange rates are, are relative. That's— but that's why gold and silver and all harder assets are going up. Against all of these currencies is because of the debasement and the devaluation and the fact that they all are going to have to monetize the debt in some way, shape, or form. And then it's okay, what sectors do you invest in? Not just gold and silver hard assets, but also medical, for example. There's a secular tailwind, not just here in the United States with this boomer generation retiring, but European boomer generation retiring. So being overweight healthcare is probably a smart move as well. And then geographic diversification. We talk a lot about having foreign exposure, not just general foreign exposure. It's also being smart with it, shifting capital to emerging markets where the population is young, it's growing, it's urbanizing. Places like South, Southeast Asia, Latin America, India. These countries will benefit from a demographic divide where countries with poor demographics— ours is not great, but it's not horrendous. China, it's really bad, right? Because the one-child policy. Europe, it's better, but still not good. So that's another reason why you want to have more exposure to these smaller countries that have a working age population that will really will be the workforce of the world for the next decades to come. Let's go answer a YouTube question. Will Road says, I think I can't think, I can't thank you enough. There we go. For the advice over the years, I would like your thoughts on an ETF with a ticker symbol XHRX. Sorry, it's XHS. XHS. This is the State Street SPDR S&P Healthcare Services. Oh, interesting. I did not plan this, promise you. He says, I will be buying it in my Roth IRA while the healthcare sector was being beaten down, or had been. It has been on a good run this last year. I'm up over 40%. I'm wondering how it looks as a long-term hold. Along those lines, what sectors should be looking towards buying that are currently beaten down? Uh, with the last part, I would say software in general, I think, is probably probably a good place.
Justin Klein — InvestTalk · Germany's Aging Population and Record Social Spending: A Preview of America's Fiscal Future? · 2026-08-27This is the Bloomberg Surveillance podcast. I'm Jonathan Ferro, along with Lisa Abramowicz and Annmarie Hordern. Join us each day for insight from the best in markets, economics, and geopolitics. From our global headquarters in New York City, we are live on Bloomberg Television weekday mornings from 6 to 9 a.m. Eastern. Subscribe to the podcast on Apple, Spotify, or anywhere else you listen. And as always, on the Bloomberg Terminal and the Bloomberg Business app. We begin this hour with stocks and yields holding steady ahead of more earnings and inflation data later this morning. Marvin Lowe of State Street writing, while recent data has thrown a bit of cold water on the strength of the economy, we don't find a reason to fade the view that the Fed will still need to tighten before year end. Marvin joins us now for more. Marvin. Good morning, sir. It's good to see you. Do you expect to get a guide from, from Kevin Walsh in a few days' time on that?
Jonathan Ferro — Bloomberg Surveillance · Bloomberg Surveillance TV: August 26th, 2026 · 2026-08-26Well-timed to speak to Simone Mikuda, chief economist at State Street, here wrapped around my exit tomorrow for Jackson Hole. We'll have all our special coverage. For you Friday. Simona, I'm with Ethan Harris, who's out on LinkedIn with brilliant notes each and every day that Mr. Warsh is going to do everything to make this a non-event. Do you agree?
Tom Keene — Bloomberg Surveillance · Bessent Intervention and Economic D-Day · 2026-08-25I mean, rock the boat is the economy. What economy do you see? I mean, we forget that all of this is wrapped around a guesstimate of Q4 and into 2027. Is it just more of the same or does State Street see an abruptness in change? To the American economy?
Tom Keene — Bloomberg Surveillance · Bessent Intervention and Economic D-Day · 2026-08-25Hey guys, Chance from Knoxville, Tennessee, calling in about KRE State Street Regional Banking ETF. Started a small position over the past few weeks, uh, with an average of $76.35 a share at around 6% of my portfolio. I wonder what you guys currently think about regional banks as well as this fund. I didn't have any exposure to financials and this was the start. So with the recent pullback, should I add more, hold and watch, or cut with a small loss? Thanks. Hope to hear the answer on the show.
Steve Peasley — InvestTalk · Financial innovation is now a Fed problem · 2026-08-22Yes, absolutely. And so, but the problem is if you were, if you bought Moderna during the last big hype cycle, even after the big run-up this week, you're still down probably 50 to 70%. Yeah. Okay. You don't even get Travis's 13% over how many years. And the, the meanwhile, the S&P, like over the last 5 years, okay, like I'm just pull up the 5-year chart on, on my, the screen here. Last 5 years, Moderna is down 60%. The market is up 73% before dividends. If you, if you are inclined to play in the biotech space, the advice I receive, the advice I will pass along is that maybe seek out a broad sector ETF focused on biotech because, and I'm just gonna pick one randomly here, the State Street SPDR S&P Biotech ETF. Okay, just there, there's a bunch of these out there. You can go look at them on Fools, but the, this one, State Street SPDR S&P Biotech. It is up 36.5% over that same 5 years. So you didn't match the market. And if you want to play in biotech, maybe it's best to spread your bets around because you don't know when a good news story— like, I mean, like, like we can all agree a cancer vaccine is amazing. If this works, it's still time to come to market. If this works, I mean, it's a net positive for humanity, obviously. But you, by the time— you can't predict unless you're a biotech expert, and I am certainly not. You really can't predict which companies and which molecules are gonna strike, and you really can't predict when they're gonna strike. And so spread your bets around. And we live in a, we live in an era when you can spread your bets around by just simply buying an exchange-traded ETF that focuses on that sector.
Jim Gillies — Motley Fool Hidden Gems Investing · Cancer Vaccines & Data Center Drama · 2026-08-21Yeah, you've seen everything from State Street to T. Rowe to Invesco. That's really the leadership within the asset— Ben's got a great chart. That's really been the leadership. In the asset management space. Interesting.
Chris Varrone — The Real Eisman Playbook · The AI Trade, Rising Rates, and Why the Market Is Still Standing | The Real Eisman Playbook Ep 73 · 2026-08-17Who else in that, in that second and third tier? I don't mean that as a term of disrespect. I mean not BlackRock, Vanguard, State Street.
Todd Sohn — The Compound and Friends · It's a bull market and nobody drinks anymore. · 2026-08-14